Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05194982 trial: what clinicians have said so far
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- NCT05194982 ↗
- Recruiting
- Sichuan Baili Pharmaceutical Co., Ltd.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05194982 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05194982 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on Bluesky, typically up to 9 once built | |
| 1 post on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumor
- Interventions
- BL-B01D1
- Arms
- Study treatment · Experimental
- Enrollment
- 570 (estimated)
- Primary outcomes
- Phase Ia: Dose limiting toxicity (DLT)
- Phase Ia: Maximum tolerated dose (MTD)
- Phase Ib: Recommended Phase II Dose (RP2D)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. with SystImmune Inc.
- Start
- Nov 29, 2021
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05194982 · updated Aug 27, 2026
Publications
linked from the registry- Zhao Y, Zhao H, Wang Q, Yang K, Li Y, Fu Z, Yang W, He Z, Wang Y, Ma Y, Yang Y, Fang W, Xiao S, Zhu H, Zhu Y, Zhang L, Huang Y. Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. J Clin Oncol. 2026 Jul 24:JCO2600243. doi: 10.1200/JCO-26-00243. Online ahead of print. PubMed 42497381
- Hong SD, Wang YS, Zhao HY, Zhao YY, Wang QM, Ma YX, Li YS, Huang Y, Yang YP, Fu ZM, Chen LK, Zhou F, Yang J, Li XY, Hou X, Zhou NN, Sun LH, Zhang GF, Cui JW, Wu L, Chen G, Zhang YX, Wang HY, Lv DQ, Shi JH, Jiang B, Li C, Li XL, Tang KJ, Yu Y, Ji YH, He ZY, Zhu Y, Zhu H, Xiao S, Zhou CC, Zhang L, Fang WF. Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann Oncol. 2026 Jun;37(6):813-824. doi: 10.1016/j.annonc.2026.01.009. Epub 2026 Jan 27. PubMed 41611210
- Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, Fang W, Guo Y, Han Y, Yang K, Li Y, Yang J, Fu Z, Chen G, Chen L, Zhou N, Zhou T, Zhang Y, Zhou H, Liu Q, Zhu Y, Zhu H, Xiao S, Zhang L, Zhao H. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024 Jul;25(7):901-911. doi: 10.1016/S1470-2045(24)00159-1. Epub 2024 May 29. PubMed 38823410